Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Signup now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/X1avXHVfmFk.

AI drug stocks haven't quite been spotted by the "let's call everything a play on generative AI" lot so they're still languishing since the last time we checked in. Names like BenevolentAI, BioXcel, and Lantern Pharma are just too small, and wrought with too many problems, to be given a serious consideration. Stick with the larger firms like Recursion, Relay Therapeutics, Exscientia, and Abcellera. As for Schrodinger, that's not an AI stock, but the only one of the lot we're holding in our own tech stock portfolio. This video takes a closer look at these seven AI drug stocks plus an honorable mention for Schrodinger and an Easter egg at the end - a Hungarian firm that wants to transform drug discovery by creating digital twins of humans.

Ver todos los episodios